Sofia Siest, PhD, was born in Athens, Greece, where she obtained a diploma of Biology. She received a PhD on Genetic Epidemiology of Cardiovascular Diseases at the University of Nancy, France.
 
    She is Director of Research at INSERM since 2001.
She has the direction of an INSERM Research Unit in Nancy: INSERM UMR U1122; “Interactions Géne-Environement en Physiopathologie Cardio-Vasculaire” (IGE-PCV) at the University of Lorraine. She has the direction of a Biological Ressources Center (BRC): “Interactions Géne-Environement en Physiopathologie Cardio-Vasculaire” (IGE-PCV) from 2002. She is the scientific director of the STANISLAS Cohort origin project based on 1,006 families followed for 15 years (STANISLAS Family Study, SFS). Dr Sophie Visvikis-Siest’s main research interests are in the domain of public health, Personalised Medicine, prevention, genetic epidemiology, genomics and pharmacogenomics, cardio-vascular diseases, VEGF and inflammation. Most of her publications are based on these topics. She has published more than 345 papers in international scientific committee journals (index h: 50, citations: 9328), 2 patents and gave more than 70 international conferences under invitation. She has a long experience in acquisition and successful execution of public, academic, industrial and EC founded projects. She participates in BBMRI (Biobanking and Biomolecular Resources Research Infrastructure) European Biobanking initiative and is one of the pioneers in Biobanking founded by INSERM and ANR in France. She has a 20-years’ experience in the prevention field by her involvement in the Center of Preventive Medicine in Vandoeuvre-lès-Nancy, France. She is Vice-President of the European Society of Predictive Medicine (EUSPM) from its creation at 2009 (www.euspm.org) and Chair of the meetings division of the European Society of Pharmacogenomics and Theranostics (ESPT) from 2011(www.esptnet.eu). She is involved in the Scientific Organization of several Congresses, Meetings and Courses, in France and abroad and she is also Responsible of her own Meetings named “Santorini Conferences” held every 2 years since 2002 in Santorini, Greece, in the domain of Genomics, Pharmacogenomics and Personalised Medicine. Relevant peer-reviewed publications:
              1. Choi SH*, Ruggiero D*, Sorice R*, …, Visvikis-Siest S, Seshadri S**, Ciullo M**. Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies. PLoS Genet. 2016 Feb 24;12(2):e1005874.
              2. Mazidi M, Rezaie P, Pascal Kengne A, Stathopoulou MG, Azimi-Nezhad M, Siest S. VEGF, the underlying factor for metabolic syndrome; fact or fiction? Diabetes Metab Syndr. 2016 (In press).
              3. Rancier M*, Zaaber I*, Stathopoulou MG, Chatelin J, Saleh A, Marmouch H, El Shamieh S, Masson C, Murray H, Lamont J, Fitzgerald P, Mahjoub S, Said K, Tensaout BB, Mestiri S, Visvikis-Siest S. Pro- and anti-angiogenic VEGF mRNAs in autoimmune thyroid diseases. Autoimmunity. 2016 Sep;49(6):366-372.
              4. Zaaber *I, Rancier M*, Stathopoulou MG, Saleh A, Marmouch H, Masson C, Murray H, Kurth MJ, Lamont J, Fitzgerald P, Mahjoub S, Said K, Bel Hadj Jrad Tensaout B, Mestiri S, Visvikis-Siest S. Plasma VEGF-related polymorphisms are implied in autoimmune thyroid diseases. Autoimmunity. 2016 Jun;49(4):229-35.
              5. Saleh A*, Stathopoulou MG*, Dadé S, Ndiaye NC, Azimi-Nezhad M, Murray H, Masson C, Lamont J, Fitzgerald P, Visvikis-Siest S. Angiogenesis related genes NOS3, CD14, MMP3 and IL4R are associated to VEGF gene expression and circulating levels in healthy adults. BMC Med Genet. 2015 Oct 5;16:90.
              6. Debette S*, Visvikis-Siest S*, Chen MH, Ndiaye NC et al. Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels. Circ Res. 2011 Aug 19; 109(5): 554-63.
              7. Azimi-Nezhad M*, Stathopoulou MG*, Bonnefond A, Rancier M, Saleh A, Lamont J, …, Visvikis-Siest S. Associations of vascular endothelial growth factor (VEGF) with adhesion and inflammation molecules in a healthy population. Cytokine. 2013 Feb; 61(2): 602-7.
              8. Stathopoulou MG*, Bonnefond A*, Ndiaye NC*, …, Visvikis-Siest S. A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. J Lipid Res. 2013 Feb; 54(2): 535-41.
              9. Bonnefond A, Saulnier PJ*, Stathopoulou MG*, Grarup N*, Ndiaye NC*, …, Visvikis-Siest S. What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications? PLoS One. 2013;8(2): e55921.
              10. Azimi-Nezhad M, Lambert D, Ottone C, Perrin C, Chapel C, Gaillard G, Pfister M, Masson C, Tabone E, Betsou F, Meyronet D, Ungeheuer MN, Siest SV. Influence of pre-analytical variables on VEGF gene expression and circulating protein concentrations. Biopreserv Biobank. 2012 Oct;10(5):454-61
              11. Berrahmoune H, Lamont JV, Herbeth B, Lambert D, Masson C, McPhillips M, Fitzgerald PS, Visvikis-Siest S. Association between EGF and lipid concentrations: a benefit role in the atherosclerotic process? Clin Chim Acta. 2009 Apr;402(1-2):196-8.
              12. Berrahmoune H, Herbeth B, Lamont JV, Masson C, Fitzgerald PS, Visvikis-Siest S. Heritability for plasma VEGF concentration in the Stanislas family study. Ann Hum Genet. 2007 Jan; 71(Pt 1): 54-63.
              13. Berrahmoune H, Lamont JV, Herbeth B, FitzGerald PS, Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: Results from the STANISLAS cohort. Clin Chem. 2006 Mar;52(3):504-10.
  *equal contribution ** equal last authors